Clinical trials: Head and Neck Cancers- Squamous Cell
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
- Trial name
- NCT01466257
- Testing
- cetuximab, cisplatin, DNA analysis
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.
- Trial name
- NCT03085719
- Testing
- Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Cancer
Study of Sorafenib/Cetuximab in Head and Neck Cancer
In this Phase I B/II trial, we seek to determine the safety and efficacy of sorafenib with standard dose cetuximab in the treatment of patients with Recurrent and /or Metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00815295
- Testing
- Sorafenib, Cetuximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Esophagus Cancer, Chemoradiotherapy
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Chemoradiotherapy（CRT） is the main treatment for esophageal cancer patients with recurrent desease，and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal cancer.
- Conditions
- Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy
- Trial name
- NCT04821765
- Testing
- PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer, Chemoradiation
Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer
The investigators designed a new preoperative chemoradiotherapy regimen to focus on the most important radiation area and hope to reduce the radiation volume and try to reduce the postoperative mortality and treatment-related…
- Conditions
- Esophageal Cancer, Chemoradiation, Surgery
- Trial name
- NCT02938195
- Testing
- radiotherapy, Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
SCCHN, Squamous Cell Carcinoma
Chemo-embolization for Head and Neck Cancer
The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer…
- Trial name
- NCT04595981
- Testing
- Cisplatin
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Esophageal Squamous Cell Carcinoma
Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by…
- Trial name
- NCT03922230
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy, Targeted Therapy
- Trial name
- NCT07040956
- Testing
- Tislelizumab, Afatinib, Low dose radiotherapy
- Where
- China
- Volunteers
- 98 people
- Sponsor
- West China Hospital
Supraglottic Cancer
Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer
Supraglottic cancer is a main type of laryngeal carcinoma, which is one of the most common head and neck tumors. Cervical nodal metastasis is an important prognostic factor in supraglottic cancer.
- Trial name
- NCT03358602
- Testing
- Radiotherapy, Selective neck dissection
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Xerostomia, Head and Neck Squamous Cell Carcinoma
Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia
This study evaluates the feasibility and safety of ultrasound-guided intraglandular dexamethasone (corticosteroid) injections into the salivary glands of patients undergoing radiation therapy for head and neck cancer.
- Trial name
- NCT07802977
- Testing
- Dexamethasone 4mg/mL, Dexamethasone 10mg/mL
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Davis
Locally Advanced Unresectable Esophageal Cancer
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
Phase II study of definitive concurrent chemoradiotherapy follows consolidative chemotherapy with S1 for locally advanced unresectable esophageal cancer.
- Trial name
- NCT06598917
- Testing
- S-1
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC)
AK129 Combination Therapy for Advanced Solid Tumors
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129…
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
- Trial name
- NCT06943820
- Testing
- AK129(dose 1), Pemetrexed, Paclitaxel
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Akeso
Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, with 25% of HNSCC patients diagnosed at over 70 years of age. As the population ages, it is expected that by 2030, this proportion will exceed 60%.
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
- Trial name
- HNSCC (NCT06768125)
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Esophageal Cancer
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00628368
- Testing
- Gene expression analysis
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.